<DOC>
	<DOC>NCT00735371</DOC>
	<brief_summary>The study will evaluate the efficacy of LDX treatment group compared to placebo on the change from Baseline ADHD-RS-IV score at endpoint.</brief_summary>
	<brief_title>Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<criteria>Meet DSMIVTR criteria for a primary diagnosis of ADHD Baseline ADHDRSIV score &gt;=28 BP w/in 95th percentile for age, gender, and height Subject has controlled or uncontrolled comorbid psychiatric diagnosis Subject has conduct disorder Suicidal Under or overweight Concurrent chronic or acute illness that might confound results.</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>